• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld MedTech

BioWorld MedTech

Aug. 2, 2021

View Archived Issues
Stylized image of a glycosylated protein

Intervenn secures $201M for cancer-focused glycoproteomics platform

Intervenn Biosciences raised $201 million in a series C financing led by new investors Softbank Group, Heritage Provider Network, Irving Investors and Highside Capital Management. The proceeds are earmarked to speed development and commercialization of Dawn, a liquid biopsy assay for immune checkpoint inhibitor prediction, and to expand the network of partnerships on the company’s artificial intelligence (AI)-driven glycoproteomics platform. Read More
Regulatory-US-FDA-HQ.png

FDA post-approval study database hints agency, industry unprepared for tighter turnaround

The FDA’s May 2021 draft guidance for post-approval studies for PMA devices did not present any regulatory novelties, but did propose tighter timelines for filing, reviewing and fulfilling post-approval study (PAS) protocols. However, a review of the agency’s PAS database suggests that both the agency and industry might have a difficult time complying with the proposed new standards for turnaround times for these studies. Read More
south-korea-flag-asia.png

Te Bios wins MFDS innovative medical device designation for artificial cornea, aims for first South Korean approval

South Korea’s Ministry of Food and Drug Safety (MFDS) has given innovative medical device designation for Te Bios Co. Ltd.’s artificial cornea, C-Clear, bringing it one step closer to becoming the first artificial cornea to be approved in the country. Read More
Illustration of Virofight concept

Virus trap: Early stage nanoshell tech aims to neutralize viruses

PARIS – At some point, scientists reported, it may be possible to quarantine viruses rather than humans. For the last two years, European research consortium Virofight has been working on a form of nanotechnology intended to neutralize viruses such as SARS-CoV-2, HIV, influenza and hepatitis viruses. Read More
Courts2.png

FTC drops Abbvie suit, relief could be short-lived

Citing a unanimous U.S. Supreme Court ruling in April that denied the Federal Trade Commission’s (FTC) ability to seek restitution or disgorgement, the FTC, on July 30, withdrew its remaining count against Abbvie Inc. involving sham litigation intended to delay generic competition to its blockbuster testosterone replacement drug, Androgel. Read More

Appointments and advancements for Aug. 2, 2021

New hires and promotions in the med-tech industry, including: Eko, Electrophysiology Frontiers, Omada Health, Pillar Biosciences, R1, Rewalk Robotics, Strata Skin Sciences, Titan Medical, Valgenesis, Windtree. Read More

Financings for Aug. 2, 2021

Med-tech firms raising money in public or private financings, including: Align, Exo. Read More

In the clinic for Aug. 2, 2021

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Mindmics, Orthofix, Xoran Technologies. Read More

Other news to note for Aug. 2, 2021

Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Blackford, Breathtek, Evonik, Jenacell, Meridian Bioscience, Paramit, Provista Diagnostics, Sense Neuro Diagnostics, Sensyne, The Tecan Group, Todos Medical. Read More

Regulatory actions for Aug. 2, 2021

Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Abbott, Realview Imaging. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 21, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 21, 2025.
  • Illustration of antibodies attacking the thyroid

    Crinetics’ TSHR antagonist demonstrates efficacy in thyroid autoimmune disorders

    BioWorld Science
    Graves disease (GD)-associated hyperthyroidism is an autoimmune disorder characterized by the presence of autoantibodies that stimulate the thyroid-stimulating...
  • Illustration of cancer cells entering the bloodstream.

    TIM3 blockade could halt breast cancer before it spreads

    BioWorld Science
    In the current landscape of cancer research, much attention is focused on the tumor microenvironment (TME) at both the primary site and established metastases....
  • MTMR14 downregulation aggravates COPD progression

    BioWorld Science
    Chronic obstructive pulmonary disease (COPD) is a respiratory disease characterized by chronic inflammation and structural damage to the alveoli, with...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe